Morten Karsdal

Morten Karsdal

Company: Nordic Bioscience

Job title: Chief Executive Officer


Is a Treatable Endotype for HFpEF the Missing Link for Successful Clinical Trials? 9:30 am

Understanding ECM signaling can give cues to better treatment strategies Endotrophin, a Type VI collagen hormone, is highly prognostic for outcome in HFpEF patients The endotrophin biomarker could be the key to identifying patients with better response to treatmentRead more

day: Day One

A Hanson Wade Group Company

© Copyright 2023 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Eastcastle House, 27/28 Eastcastle Street, London, W1W 8DH.